Erschienen in:
01.08.2008 | Editorial
NICE continues to muddy the waters of osteoporosis
verfasst von:
J. A. Kanis, J. E. Compston
Erschienen in:
Osteoporosis International
|
Ausgabe 8/2008
Einloggen, um Zugang zu erhalten
Excerpt
The storm generated by the National Institute for Health and Clinical Excellence (NICE) over the appraisal of osteoporosis treatments in the UK continues unabated. An editorial in
Bone earlier this year outlined the history of the prolonged appraisal process, begun in 2002, that continues to evaluate the cost-effectiveness of interventions for the primary and secondary prevention of osteoporotic fractures [
1]. At that time NICE had issued its Final Appraisal Determinations (FADs) for primary and secondary prevention that restricted the use of interventions to generic alendronate [
2,
3]. The appraisal was successfully appealed for this and other reasons. As a result, further consultation documents have been issued [
4,
5]. The new documents now include appraisals for other treatments, including risedronate, raloxifene, strontium ranelate and (for secondary prevention only) teriparatide. Other changes have been microscopic despite public and private concern. What are these concerns, and why should they trouble the international readership of
Osteoporosis International? …
